NASDAQ:EDIT

Editas Medicine Stock Predictions

etoro logo Buy EDIT
*Your capital is at risk
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

EDIT Prediction Chart

EDIT Predictions History

Latest community submissions for EDIT.
Predictor Target Session Target Price Result Direction Accuracy Score
JS JS Pro
Jan 28, 2021 $59.32 -2.96% $61.13 X 97.04% 0
David King David King @DavidKing.189476
Jan 28, 2021 Bullish $61.13 X 1
JS JS Pro
Jan 11, 2021 $88.09 +14.49% $76.94 X 85.51% 1
Xx X Xx X @XxX.187554
Jan 11, 2021 Bullish $76.94 X 0
JS JS Pro
Jan 5, 2021 $72.96 -5.05% $76.84 X 94.95% 1
Brent Ushijima Brent Ushijima @BrentUshijima.182220
Jan 5, 2021 Bearish $76.84 X 0
JS JS Pro
Mar 5, 2020 $24.28 -3.46% $25.15 X 96.54% 1
Eitan Yehoshua Eitan Yehoshua @EitanYehoshua.133763
Mar 5, 2020 $24.00 -4.57% $25.15 X 95.43% 1
gabitul g gabitul g @gabitulg.143551
Mar 5, 2020 Bullish $25.15 X 1
2poJeff 2poJeff Pro
Mar 5, 2020 $22.56 -10.30% $25.15 X 89.70% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for EDIT with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT EDITAS MEDICINE, INC
Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE